Concise review: Roles of polycomb group proteins in development and disease: A stem cell perspective

Stem Cells

Volumn 25, Issue 10, 2007, Pages 2498-2510

  Rajasekhar, Vinagolu K ^a   Begemann, Martin ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

Adult stem cells; Cancer stem cells; Chromatin; DNA methylation; Embryonic stem cells; Epigenetic control; Histones; Pluripotency; Polycomb group proteins; Self renewal

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN;

CHROMATIN; DNA BINDING; EMBRYONIC STEM CELL; EPIGENETICS; GENE EXPRESSION; HUMAN; NONHUMAN; REVIEW; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STEM CELL;

ANIMALS; CELL DIFFERENTIATION; CELL LINEAGE; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIN; EMBRYONIC DEVELOPMENT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE SILENCING; GENES, HOMEOBOX; HUMANS; MICE; NEOPLASTIC STEM CELLS; PROMOTER REGIONS (GENETICS); REGULATORY ELEMENTS, TRANSCRIPTIONAL; REPRESSOR PROTEINS; STEM CELLS;

METAZOA;

EID: 35348850693     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.2006-0608     Document Type: Review

References (243)

1. Waddington CH. The epigenotype. Endeavour 1942;1:18-20.
2. Grimaud C, Negre N, Cavalli G. From genetics to epigenetics: The tale of Polycomb group and trithorax group genes. Chromosome Res 2006;14:363-375.
3. Richards EJ. Inherited epigenetic variation - revisiting soft inheritance. Nat Rev Genet 2006;7:395-401.
4. Orlando V. Polycomb, epigenomes, and control of cell identity. Cell 2003;112:599-606.
5. Ptashne M. On the use of the word 'epigenetic.' Curr Biol 2007;17:R233-236.
6. Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007;128:669-681.
7. Gottschling DE. Summary: Epigenetics - from phenomenon to field. Cold Spring Harb Symp Quant Biol 2004;69:507-519.
8. Ptashne M, Johnson AD, Pabo CO. A genetic switch in a bacterial virus. Sci Am 1982;247:128-130, 132, 134-140.
9. Jaenisch R, Bird A. Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 2003;33:245-254.
10. Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell 2004;118:409-418.
11. Morgan HD, Santos F, Green K et al. Epigenetic reprogramming in mammals. Hum Mol Genet 2005;14 Spec No 1:R47-58.
12. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006;6:846-856.
13. Lotem J, Sachs L. Epigenetics and the plasticity of differentiation in normal and cancer stem cells. Oncogene 2006;25:7663-7672.
14. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
15. Ting AH, McGarvey KM, Baylin SB. The cancer epigenome - components and functional correlates. Genes Dev 2006;20:3215-3231.
16. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007;128:683-692.
17. Surani MA, Hayashi K, Hajkova P. Genetic and epigenetic regulators of pluripotency. Cell 2007;128:747-762.
18. Spivakov M, Fisher AG. Epigenetic signatures of stem-cell identity. Nat Rev Genet 2007;8:263-271.
19. Misteli T. Beyond the sequence: Cellular organization of genome function. Cell 2007;128:787-800.
20. Barrera LO, Ren B. The transcriptional regulatory code of eukaryotic cells - insights from genome-wide analysis of chromatin organization and transcription factor binding. Curr Opin Cell Biol 2006;18:291-298.
21. Quina AS, Buschbeck M, Di Croce L. Chromatin structure and epigenetics. Biochem Pharmacol 2006;72:1563-1569.
22. Narlikar GJ, Fan HY, Kingston RE. Cooperation between complexes that regulate chromatin structure and transcription. Cell 2002;108:475-487.
23. Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007;128:707-719.
24. Rea S, Eisenhaber F, O'Carroll D et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000;406:593-599.
25. Gan Q, Yoshida T, McDonald OG et al. Concise review: Epigenetic mechanisms contribute to pluripotency and cell lineage determination of embryonic stem cells. STEM CELLS 2007;25:2-9.
26. Klose RJ, Bird AP. Genomic DNA methylation: The mark and its mediators. Trends Biochem Sci 2006;31:89-97.
27. Takai D, Jones PA. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci U S A 2002;99:3740-3745.
28. Ramsahoye BH, Biniszkiewicz D, Lyko F et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc Natl Acad Sci U S A 2000;97:5237-5242.
29. Simonsson S, Gurdon J. DNA demethylation is necessary for the epigenetic reprogramming of somatic cell nuclei. Nat Cell Biol 2004;6:984-990.
30. Schaefer CB, Ooi SK, Bestor TH et al. Epigenetic decisions in mammalian germ cells. Science 2007;316:398-399.
31. Lagarkova MA, Volchkov PY, Lyakisheva AV et al. Diverse epigenetic profile of novel human embryonic stem cell lines. Cell Cycle 2006;5:416-420.
32. Gilbert N, Thomson I, Boyle S et al. DNA methylation affects nuclear organization, histone modifications, and linker histone binding but not chromatin compaction. J Cell Biol 2007;177:401-411.
33. Jones PL, Veenstra GJ, Wade PA et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187-191.
34. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386-389.
35. Ringrose L. Polycomb, trithorax and the decision to differentiate. Bioessays 2006;28:330-334.
36. Schwartz YB, Pirrotta V. Polycomb silencing mechanisms and the management of genomic programmes. Nat Rev Genet 2007;8:9-22.
37. Schuettengruber B, Chourrout D, Vervoort M et al. Genome regulation by polycomb and trithorax proteins. Cell 2007;128:735-745.
38. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annu Rev Genet 2004;38:413-443.
39. Barski A, Cuddapah S, Cui K et al. High-resolution profiling of histone methylations in the human genome. Cell 2007;129:823-837.
40. Ringrose L, Paro R. Polycomb/Trithorax response elements and epigenetic memory of cell identity. Development 2007;134:223-232.
41. Bernstein BE, Kamal M, Lindblad-Toh K et al. Genomic maps and comparative analysis of histone modifications in human and mouse. Cell 2005;120:169-181.
42. Kim TH, Barrera LO, Zheng M et al. A high-resolution map of active promoters in the human genome. Nature 2005;436:876-880.
43. Roh TY, Cuddapah S, Cui K et al. The genomic landscape of histone modifications in human T cells. Proc Natl Acad Sci U S A 2006;103:15782-15787.
44. Martinez AM, Cavalli G. The role of polycomb group proteins in cell cycle regulation during development. Cell Cycle 2006;5:1189-1197.
45. Su IH, Dobenecker MW, Dickinson E et al. Polycomb group protein ezh2 controls actin polymerization and cell signaling. Cell 2005;121:425-436.
46. Guney I, Sedivy JM. Cellular senescence, epigenetic switches and c-Myc. Cell Cycle 2006;5:2319-2323.
47. Heard E. Delving into the diversity of facultative heterochromatin: The epigenetics of the inactive X chromosome. Curr Opin Genet Dev 2005;15:482-489.
48. Mager J, Montgomery ND, de Villena FP et al. Genome imprinting regulated by the mouse Polycomb group protein Eed. Nat Genet 2003;33:502-507.
49. Hosokawa H, Kimura MY, Shinnakasu R et al. Regulation of Th2 cell development by Polycomb group gene bmi-1 through the stabilization of GATA3. J Immunol 2006;177:7656-7664.
50. Oguro H, Iwama A, Morita Y et al. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med 2006;203:2247-2253.
51. Almeida R, Allshire RC. RNA silencing and genome regulation. Trends Cell Biol 2005;15:251-258.
52. Grimaud C, Bantignies F, Pal-Bhadra M et al. RNAi components are required for nuclear clustering of Polycomb group response elements. Cell 2006;124:957-971.
53. Lin H. piRNAs in the germ line. Science 2007;316:397.
54. Bernstein E, Duncan EM, Masui O et al. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol 2006;26:2560-2569.
55. Zaratiegui M, Irvine DV, Martienssen RA. Noncoding RNAs and gene silencing. Cell 2007;128:763-776.
56. Yang PK, Kuroda MI. Noncoding RNAs and intranuclear positioning in monoallelic gene expression. Cell 2007;128:777-786.
57. Bernstein E, Allis CD. RNA meets chromatin. Genes Dev 2005;19:1635-1655.
58. Kim DH, Villeneuve LM, Morris KV et al. Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat Struct Mol Biol 2006;13:793-797.
59. Cheng LC, Tavazoie M, Doetsch F. Stem cells: From epigenetics to microRNAs. Neuron 2005;46:363-367.
60. Lee TI, Jenner RG, Boyer LA et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 2006;125:301-313.
61. Saito Y, Jones PA. Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 2006;5:2220-2222.
62. Lewis EB. A gene complex controlling segmentation in Drosophila. Nature 1978;276:565-570.
63. Struhl G. A gene product required for correct initiation of segmental determination in Drosophila. Nature 1981;293:36-41.
64. Levine SS, King IF, Kingston RE. Division of labor in polycomb group repression. Trends Biochem Sci 2004;29:478-485.
65. Groth A, Rocha W, Verreault A et al. Chromatin challenges during DNA replication and repair. Cell 2007;128:721-733.
66. Pasini D, Bracken AP, Jensen MR et al. Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J 2004;23:4061-4071.
67. O'Carroll D, Erhardt S, Pagani M et al. The polycomb-group gene Ezh2 is required for early mouse development. Mol Cell Biol 2001;21:4330-4336.
68. Faust C, Schumacher A, Holdener B et al. The eed mutation disrupts anterior mesoderm production in mice. Development 1995;121:273-285.
69. Tolhuis B, Muijrers I, de Wit E et al. Genome-wide profiling of PRC1 and PRC2 Polycomb chromatin binding in Drosophila melanogaster. Nat Genet 2006;38:694-699.
70. Schwartz YB, Kahn TG, Nix DA et al. Genome-wide analysis of Polycomb targets in Drosophila melanogaster. Nat Genet 2006;38:700-705.
71. Cao R, Zhang Y. SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 2004;15:57-67.
72. Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell 2005;20:845-854.
73. Kuzmichev A, Jenuwein T, Tempst P et al. Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. Mol Cell 2004;14:183-193.
74. Boyer LA, Mathur D, Jaenisch R. Molecular control of pluripotency. Curr Opin Genet Dev 2006;16:455-462.
75. Voncken JW, Roelen BA, Roefs M et al. Rnf2 (Ring1b) deficiency causes gastrulation arrest and cell cycle inhibition. Proc Natl Acad Sci U S A 2003;100:2468-2473.
76. Isono K, Fujimura Y, Shinga J et al. Mammalian polyhomeotic homo-logues Phc2 and Phc1 act in synergy to mediate polycomb repression of Hox genes. Mol Cell Biol 2005;25:6694-6706.
77. Jorgensen HF, Giadrossi S, Casanova M et al. Stem cells primed for action: Polycomb repressive complexes restrain the expression of lineage-specific regulators in embryonic stem cells. Cell Cycle 2006;5:1411-1414.
78. Bracken AP, Dietrich N, Pasini D et al. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev 2006;20:1123-1136.
79. de la Cruz CC, Kirmizis A, Simon MD et al. The polycomb group protein SUZ12 regulates histone H3 lysine 9 methylation and HP1alpha distribution. Chromosome Res 2007;15:299-314.
80. de Wit E, Greil F, van Steensel B. High-resolution mapping reveals links of HP1 with active and inactive chromatin components. PLoS Genet 2007;3:e38.
81. Chen X, Hiller M, Sancak Y et al. Tissue-specific TAFs counteract Polycomb to turn on terminal differentiation. Science 2005;310:869-872.
82. Chopra VS, Mishra RK. To SIR with Polycomb: linking silencing mechanisms. Bioessays 2005;27:119-121.
83. Lund AH, van Lohuizen M. Epigenetics and cancer. Genes Dev 2004;18:2315-2335.
84. Lund AH, van Lohuizen M. Polycomb complexes and silencing mechanisms. Curr Opin Cell Biol 2004;16:239-246.
85. Kuzmichev A, Margueron R, Vaquero A et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A 2005;102:1859-1864.
86. Varambally S, Dhanasekaran SM, Zhou M et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-629.
87. Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005;24:117-125.
88. Kouzarides T. Chromatin modifications and their function. Cell 2007;128:693-705.
89. Strutt H, Paro R. The polycomb group protein complex of Drosophila melanogaster has different compositions at different target genes. Mol Cell Biol 1997;17:6773-6783.
90. Su IH, Tarakhovsky A. Lysine methylation and 'signaling memory.' Curr Opin Immunol 2006;18:152-157.
91. Voncken JW, Schweizer D, Aagaard L et al. Chromatin-association of the Polycomb group protein BMI1 is cell cycle-regulated and correlates with its phosphorylation status. J Cell Sci 1999;112:4627-4639.
92. Vire E, Brenner C, Deplus R et al. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006;439:871-874.
93. Taghavi P, van Lohuizen M. Developmental biology: Two paths to silence merge. Nature 2006;439:794-795.
94. Hernandez-Munoz I, Taghavi P, Kuijl C et al. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1. Mol Cell Biol 2005;25:11047-11058.
95. Torres-Padilla ME, Parfitt DE, Kouzarides T et al. Histone arginine methylation regulates pluripotency in the early mouse embryo. Nature 2007;445:214-218.
96. Rajasekhar VK, Vemuri MC. Molecular insights into the function, fate, and prospects of stem cells. STEM CELLS 2005;23:1212-1220.
97. Rando TA. Stem cells, ageing and the quest for immortality. Nature 2006;441:1080-1086.
98. Kerr CL, Shamblott MJ, Gearhart JD. Pluripotent stem cells from germ cells. Methods Enzymol 2006;419:400-426.
99. Iwama A, Oguro H, Negishi M et al. Epigenetic regulation of hematopoietic stem cell self-renewal by polycomb group genes. Int J Hematol 2005;81:294-300.
100. de la Cruz CC, Fang J, Plath K et al. Developmental regulation of Suz 12 localization. Chromosoma 2005;114:183-192.
101. Pasini D, Bracken AP, Hansen JB et al. The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol 2007;27:3769-3779.
102. Erhardt S, Su IH, Schneider R et al. Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development. Development 2003;130:4235-4248.
103. Meshorer E, Misteli T. Chromatin in pluripotent embryonic stem cells and differentiation. Nat Rev Mol Cell Biol 2006;7:540-546.
104. Boyer LA, Plath K, Zeitlinger J et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006;441:349-353.
105. Azuara V, Perry P, Sauer S et al. Chromatin signatures of pluripotent cell lines. Nat Cell Biol 2006;8:532-538.
106. Tada T. Toti-/pluripotential stem cells and epigenetic modifications. Neurodegener Dis 2006;3:32-37.
107. Boyer LA, Lee TI, Cole MF et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-956.
108. Loh YH, Wu Q, Chew JL et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 2006;38:431-440.
109. Squazzo SL, O'Geen H, Komashko VM et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res 2006;16:890-900.
110. de Haan G. Epigenetic control of hematopoietic stem cell aging, the case of Ezh2. Ann N Y Acad Sci 2007 [Epub ahead of print].
111. Yeoh JS, de Haan G. Fibroblast growth factors as regulators of stem cell self-renewal and aging. Mech Ageing Dev 2007;128:17-24.
112. Kamminga LM, de Haan G. Cellular memory and hematopoietic stem cell aging. STEM CELLS 2006;24:1143-1149.
113. Kamminga LM, Bystrykh LV, de Boer A et al. The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood 2006;107:2170-2179.
114. Iwama A, Oguro H, Negishi M et al. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1. Immunity 2004;21:843-851.
115. Lessard J, Schumacher A, Thorsteinsdottir U et al. Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. Genes Dev 1999;13:2691-2703.
116. Leung C, Lingbeek M, Shakhova O et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 2004;428:337-341.
117. Molofsky AV, He S, Bydon M et al. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev 2005;19:1432-1437.
118. Molofsky AV, Pardal R, Iwashita T et al. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 2003;425:962-967.
119. Caretti G, Di Padova M, Micales B et al. The Polycomb Ezh2 methyl-transferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev 2004;18:2627-2638.
120. Bibikova M, Chudin E, Wu B et al. Human embryonic stem cells have a unique epigenetic signature. Genome Res 2006;16:1075-1083.
121. Zvetkova I, Apedaile A, Ramsahoye B et al. Global hypomethylation of the genome in XX embryonic stem cells. Nat Genet 2005;37:1274-1279.
122. Sado T, Okano M, Li E et al. De novo DNA methylation is dispensable for the initiation and propagation of X chromosome inactivation. Development 2004;131:975-982.
123. Lehnertz B, Ueda Y, Derijck AA et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 2003;13:1192-1200.
124. Mermoud JE, Popova B, Peters AH et al. Histone H3 lysine 9 methylation occurs rapidly at the onset of random X chromosome inactivation. Curr Biol 2002;12:247-251.
125. Maitra A, Arking DE, Shivapurkar N et al. Genomic alterations in cultured human embryonic stem cells. Nat Genet 2005;37:1099-1103.
126. Tada M, Tada T, Lefebvre L et al. Embryonic germ cells induce epigenetic reprogramming of somatic nucleus in hybrid cells. EMBO J 1997;16:6510-6520.
127. Wang J, Mager J, Chen Y et al. Imprinted X inactivation maintained by a mouse Polycomb group gene. Nat Genet 2001;28:371-375.
128. Takagi N, Sasaki M. Preferential inactivation of the paternally derived X chromosome in the extraembryonic membranes of the mouse. Nature 1975;256:640-642.
129. Muyrers-Chen I, Hernandez-Munoz I, Lund AH et al. Emerging roles of Polycomb silencing in X-inactivation and stem cell maintenance. Cold Spring Harb Symp Quant Biol 2004;69:319-326.
130. Kalantry S, Magnuson T. The Polycomb group protein EED is dispensable for the initiation of random X-chromosome inactivation. PLoS Genet 2006;2:e66.
131. Kalantry S, Mills KC, Yee D et al. The Polycomb group protein Eed protects the inactive X-chromosome from differentiation-induced reactivation. Nat Cell Biol 2006;8:195-202.
132. Mak W, Nesterova TB, de Napoles M et al. Reactivation of the paternal X chromosome in early mouse embryos. Science 2004;303:666-669.
133. de Napoles M, Mermoud JE, Wakao R et al. Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation. Dev Cell 2004;7:663-676.
134. McLaren A. Primordial germ cells in the mouse. Dev Biol 2003;262:1-15.
135. Surani MA, Ancelin K, Hajkova P et al. Mechanism of mouse germ cell specification: A genetic program regulating epigenetic reprogramming. Cold Spring Harb Symp Quant Biol 2004;69:1-9.
136. McLaren A, Monk M. X-chromosome activity in the germ cells of sex-reversed mouse embryos. J Reprod Fertil 1981;63:533-537.
137. Bernstein BE, Mikkelsen TS, Xie X et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006;125:315-326.
138. Negre N, Hennetin J, Sun LV et al. Chromosomal distribution of PcG proteins during Drosophila development. PLoS Biol 2006;4:e170.
139. Dejardin J, Rappailles A, Cuvier O et al. Recruitment of Drosophila Polycomb group proteins to chromatin by DSP1. Nature 2005;434:533-538.
140. Gabellini D, Green MR, Tupler R. Inappropriate gene activation in FSHD: A repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 2002;110:339-348.
141. Kimura H, Tada M, Nakatsuji N et al. Histone code modifications on pluripotential nuclei of reprogrammed somatic cells. Mol Cell Biol 2004;24:5710-5720.
142. Mellor J. Dynamic nucleosomes and gene transcription. Trends Genet 2006;22:320-329.
143. Orlando V, Jane EP, Chinwalla V et al. Binding of trithorax and Polycomb proteins to the bithorax complex: Dynamic changes during early Drosophila embryogenesis. EMBO J 1998;17:5141-5150.
144. Morrison SJ, Kimble J. Asymmetric and symmetric stem-cell divisions in development and cancer. Nature 2006;441:1068-1074.
145. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
146. Enver T, Soneji S, Joshi C et al. Cellular differentiation hierarchies in normal and culture-adapted human embryonic stem cells. Hum Mol Genet 2005;14:3129-3140.
147. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-428.
148. Frigola J, Song J, Stirzaker C et al. Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 2006;38:540-549.
149. Cadieux B, Ching TT, Vandenberg SR et al. Genome-wide hypomethylation in human glioblastomas associated with specific copy number alteration, methylenetetrahydrofolate reductase allele status, and increased proliferation. Cancer Res 2006;66:8469-8476.
150. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007;8:286-298.
151. Fraga MF, Ballestar E, Villar-Garea A et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37:391-400.
152. Seligson DB, Horvath S, Shi T et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-1266.
153. Widschwendter M, Fiegl H, Egle D et al. Epigenetic stem cell signature in cancer. Nat Genet 2007;39:157-158.
154. Pasini D, Bracken AP, Helin K. Polycomb group proteins in cell cycle progression and cancer. Cell Cycle 2004;3:396-400.
155. Raaphorst FM. Of mice, flies, and man: The emerging role of polycomb-group genes in human malignant lymphomas. Int J Hematol 2005;81:281-287.
156. Bracken AP, Pasini D, Capra M et al. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-5335.
157. Tan J, Yang X, Zhuang L et al. Pharmacologic disruption of Polycombrepressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007;21:1050-1063.
158. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902.
159. Parrish JZ, Emoto K, Jan LY et al. Polycomb genes interact with the tumor suppressor genes hippo and warts in the maintenance of Drosophila sensory neuron dendrites. Genes Dev 2007;21:956-972.
160. Pardal R, Molofsky AV, He S et al. Stem cell self-renewal and cancer cell proliferation are regulated by common networks that balance the activation of proto-oncogenes and tumor suppressors. Cold Spring Harb Symp Quant Biol 2005;70:177-185.
161. Sharpless NE, DePinho RA. Cancer: Crime and punishment. Nature 2005;436:636-637.
162. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-233.
163. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
164. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-116.
165. Reya T, Morrison SJ, Clarke MF et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-111.
166. Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea - a paradigm shift. Cancer Res 2006;66:1883-1890.
167. Clarke MF, Fuller M. Stem cells and cancer: Two faces of eve. Cell 2006;124:1111-1115.
168. Ohm JE, McGarvey KM, Yu X et al. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 2007;39:237-242.
169. Dahiya A, Wong S, Gonzalo S et al. Linking the Rb and polycomb pathways. Mol Cell 2001;8:557-569.
170. Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene 2001;20:8085-8091.
171. Ezeh UI, Turek PJ, Reijo RA et al. Human embryonic stem cell genes OCT4, NANOG, STELLAR, and GDF3 are expressed in both seminoma and breast carcinoma. Cancer 2005;104:2255-2265.
172. Gidekel S, Pizov G, Bergman Y et al. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 2003;4:361-370.
173. Hochedlinger K, Blelloch R, Brennan C et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev 2004;18:1875-1885.
174. Hochedlinger K, Yamada Y, Beard C et al. Ectopic expression of Oct-4 blocks progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005;121:465-477.
175. Margueron R, Trojer P, Reinberg D. The key to development: Interpreting the histone code? Curr Opin Genet Dev 2005;15:163-176.
176. Schlesinger Y, Straussman R, Keshet I et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007;39:232-236.
177. Ohm JE, Baylin SB. Stem cell chromatin patterns: An instructive mechanism for DNA hypermethylation? Cell Cycle 2007;6:1040-1043.
178. Esteller M. Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. Br J Cancer 2007;96:R26-30.
179. Jacobs JJ, Kieboom K, Marino S et al. The oncogene and Polycombgroup gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999;397:164-168.
180. Molofsky AV, Slutsky SG, Joseph NM et al. Increasing p16INK4a expression decreases forebrain progenitors and neurogenesis during ageing. Nature 2006;443:448-452.
181. Bruggeman SW, Valk-Lingbeek ME, van der Stoop PP et al. Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. Genes Dev 2005;19:1438-1443.
182. Kotake Y, Cao R, Viatour P et al. pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 2007;21:49-54.
183. Bracken AP, Kleine-Kohlbrecher D, Dietrich N et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 2007;21:525-530.
184. Janzen V, Forkert R, Fleming HE et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 2006;443:421-426.
185. Krishnamurthy J, Ramsey MR, Ligon KL et al. p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006;443:453-457.
186. Ding L, Erdmann C, Chinnaiyan AM et al. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res 2006;66:4095-4099.
187. Fiskus W, Pranpat M, Balasis M et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006;5:3096-3104.
188. McGarvey KM, Fahrner JA, Greene E et al. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006;66:3541-3549.
189. Baglole CJ, Ray DM, Bernstein SH et al. More than structural cells, fibroblasts create and orchestrate the tumor microenvironment. Immunol Invest 2006;35:297-325.
190. Moore KA, Lemischka IR. Stem cells and their niches. Science 2006;311:1880-1885.
191. Bissell MJ, Labarge MA. Context, tissue plasticity, and cancer: Are tumor stem cells also regulated by the microenvironment? Cancer Cell 2005;7:17-23.
192. Li L, Neaves WB. Normal stem cells and cancer stem cells: The niche matters. Cancer Res 2006;66:4553-4557.
193. Hu M, Yao J, Cai L et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005;37:899-905.
194. Pritsker M, Ford NR, Jenq HT et al. Genomewide gain-of-function genetic screen identifies functionally active genes in mouse embryonic stem cells. Proc Natl Acad Sci U S A 2006;103:6946-6951.
195. Cavalli G. Chromatin and epigenetics in development: Blending cellular memory with cell fate plasticity. Development 2006;133:2089-2094.
196. Orkin SH. Chipping away at the embryonic stem cell network. Cell 2005;122:828-830.
197. Lee H, Habas R, Abate-Shen C. MSX1 cooperates with histone H1b for inhibition of transcription and myogenesis. Science 2004;304:1675-1678.
198. Lee H, Quinn JC, Prasanth KV et al. PIAS1 confers DNA-binding specificity on the Msx1 homeoprotein. Genes Dev 2006;20:784-794.
199. Chagraoui J, Niessen SL, Lessard J et al. E4F1: A novel candidate factor for mediating BMI1 function in primitive hematopoietic cells. Genes Dev 2006;20:2110-2120.
200. Mohd-Sarip A, van der Knaap JA, Wyman C et al. Architecture of a polycomb nucleoprotein complex. Mol Cell 2006;24:91-100.
201. Rajasekhar VK. Analytical methods for cancer stem cells. In: Vemuri MC, ed. Stem Cell Assays. Totowa, NJ: Humana Press, 2007:83-95.
202. Wegel E, Shaw P. Gene activation and deactivation related changes in the three-dimensional structure of chromatin. Chromosoma 2005;114:331-337.
203. Beck HC, Nielsen EC, Matthiesen R et al. Quantitative proteomic analysis of post-translational modifications of human histones. Mol Cell Proteomics 2006;5:1314-1325.
204. Heintzman ND, Stuart RK, Hon G et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007;39:311-318.
205. O'Neill LP, VerMilyea MD, Turner BM. Epigenetic characterization of the early embryo with a chromatin immunoprecipitation protocol applicable to small cell populations. Nat Genet 2006;38:835-841.
206. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006;126:663-676.
207. Wernig M, Meissner A, Foreman R et al. In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature 2007 [Epub ahead of print].
208. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007 [Epub ahead of print].
209. Maherali N, Sridharan R, Xie W et al. Directly reprogrammed fibroblasts show global epigenetic remodeling and wide spread tissue contribution. Cell Stem Cell 2007;1:55-70.
210. Bantignies F, Cavalli G. Cellular memory and dynamic regulation of polycomb group proteins. Curr Opin Cell Biol 2006;18:275-283.
211. Berezovska OP, Glinskii AB, Yang Z et al. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006;5:1886-1901.
212. Sanchez-Beato M, Sanchez E, Gonzalez-Carrero J et al. Variability in the expression of polycomb proteins in different normal and tumoral tissues. A pilot study using tissue microarrays. Mod Pathol 2006;19:684-694.
213. Bea S, Tort F, Pinyol M et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001;61:2409-2412.
214. Saramaki OR, Tammela TL, Martikainen PM et al. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006;45:639-645.
215. Tokimasa S, Ohta H, Sawada A et al. Lack of the Polycomb-group gene rae28 causes maturation arrest at the early B-cell developmental stage. Exp Hematol 2001;29:93-103.
216. van Kemenade FJ, Raaphorst FM, Blokzijl T et al. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 2001;97:3896-3901.
217. Arisan S, Buyuktuncer ED, Palavan-Unsal N et al. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol Int 2005;75:252-257.
218. Weikert S, Christoph F, Kollermann J et al. Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 2005;16:349-353.
219. Raman JD, Mongan NP, Tickoo SK et al. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin Cancer Res 2005;11:8570-8576.
220. Collett K, Eide GE, Arnes J et al. Expression of enhancer of zeste
221. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 2006;24:268-273.
222. Kleer CG, Cao Q, Varambally S et al. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 2003;100:11606-11611.
223. Mimori K, Ogawa K, Okamoto M et al. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur J Surg Oncol 2005;31:376-380.
224. Raaphorst FM, van Kemenade FJ, Blokzijl T et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol 2000;157:709-715.
225. Sudo T, Utsunomiya T, Mimori K et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer 2005;92:1754-1758.
226. Visser HP, Gunster MJ, Kluin-Nelemans HC et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001;112:950-958.
227. van Leenders GJ, Dukers D, Hessels D et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007;52:455-463.
228. Beke L, Nuytten M, Van Eynde A et al. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2. Oncogene 2007;26:4590-4595.
229. Chen H, Tu SW, Hsieh JT. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer. J Biol Chem 2005;280:22437-22444.
230. Matsukawa Y, Semba S, Kato H et al. Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci 2006;97:484-491.
231. Kirmizis A, Bartley SM, Farnham PJ. Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2003;2:113-121.
232. Breuer RH, Snijders PJ, Smit EF et al. Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia 2004;6:736-743.
233. Tateishi K, Ohta M, Kanai F et al. Dysregulated expression of stem cell factor Bmi1 in precancerous lesions of the gastrointestinal tract. Clin Cancer Res 2006;12:6960-6966.
234. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-978.
235. Dukers DF, van Galen JC, Giroth C et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol 2004;164:873-881.
236. Sawa M, Yamamoto K, Yokozawa T et al. BMI-1 is highly expressed in M0-subtype acute myeloid leukemia. Int J Hematol 2005;82:42-47.
237. Song LB, Zeng MS, Liao WT et al. Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res 2006;66:6225-6232.
238. Nowak K, Kerl K, Fehr D et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res 2006;34:1745-1754.
239. Vonlanthen S, Heighway J, Altermatt HJ et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001;84:1372-1376.
240. Breuer RH, Snijders PJ, Sutedja GT et al. Expression of the p16(INK4a) gene product, methylation of the p16(INK4a) promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesions. Lung Cancer 2005;48:299-306.
241. Kang MK, Kim RH, Kim SJ et al. Elevated Bmi-1 expression is associated with dysplastic cell transformation during oral carcinogenesis and is required for cancer cell replication and survival. Br J Cancer 2007;96:126-133.
242. Gordon S, Akopyan G, Garban H et al. Transcription factor YY1: Structure, function, and therapeutic implications in cancer biology. Oncogene 2006;25:1125-1142.
243. Wang S, He F, Xiong W et al. Polycomblike-2-deficient mice exhibit normal left-right asymmetry. Dev Dyn 2007;236:853-861.